Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Boston Scientific Corporation. A complete text table follows the diagram.
Minimally invasive cardiovascular platforms now supply two-thirds of sales, while the MedSurg portfolio extends the same device model across more procedures.
Swipe to explore
The $2.092B Other Cardiovascular node is the reported $3.503B segment less EP and Watchman. MedSurg uses its three reported business lines, which sum to $1.700B; together the selected product categories equal $5.203B of consolidated sales. Cost of products is shown as the $1.589B arithmetic difference between rounded sales and gross profit because the filing displays that cost as $1.590B after rounding.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Electrophysiology | 1 | $905M | Mapping and treating heart rhythm disorders |
| Watchman | 1 | $506M | Left atrial appendage closure |
| Other cardiovascular therapies | 1 | $2.1B | Interventional, rhythm and oncology devices |
| MedSurg | 1 | $1.7B | Endoscopy, urology and neuromodulation |
| Medical-device sales | 2 | $5.2B | 11.6% reported growth |
| Manufacture the device portfolio | 3 | $1.6B | Arithmetic difference to rounded gross profit |
| Gross profit | 3 | $3.6B | 69.5% of sales |
| Clinical selling, R&D & portfolio costs | 4 | $2.5B | Reported total operating expenses |
| Operating income | 4 | $1.1B | 21.2% operating margin |
| Net other income | 4 | $61M | Other income less interest expense |
| Income before tax | 5 | $1.2B | Reported pretax result |
| Income-tax benefit | 5 | $176M | Reported benefit |
| Rounding | 5 | $1M | Rounded statement reconciliation |
| Net income | 6 | $1.3B | Reported consolidated result |
| Noncontrolling-interest loss | 6 | $2M | Added in attribution |
| Income attributable to common stockholders | 7 | $1.3B | $0.90 per diluted share |
| From | To | Value |
|---|---|---|
| Electrophysiology | Medical-device sales | $905M |
| Watchman | Medical-device sales | $506M |
| Other cardiovascular therapies | Medical-device sales | $2.1B |
| MedSurg | Medical-device sales | $1.7B |
| Medical-device sales | Manufacture the device portfolio | $1.6B |
| Medical-device sales | Gross profit | $3.6B |
| Gross profit | Clinical selling, R&D & portfolio costs | $2.5B |
| Gross profit | Operating income | $1.1B |
| Operating income | Income before tax | $1.1B |
| Net other income | Income before tax | $61M |
| Income before tax | Net income | $1.2B |
| Income-tax benefit | Net income | $176M |
| Rounding | Net income | $1M |
| Net income | Income attributable to common stockholders | $1.3B |
| Noncontrolling-interest loss | Income attributable to common stockholders | $2M |